(NewsDirect)
ECO Animal Health Group PLC (AIM: EAH) CEODavid Hallas speaks to Thomas Warner from Proactive about thecompany's recent performance and his hopes for its future, duringhis first interview on the platform. Hallas starts by giving anoverview of the business, which specialises in developing, registeringand marketing pharmaceutical products for global animal health marketsand particularly for pigs and chickens.
The company's flagship product Aivlosin is a proprietary,patented medication which is effective against both respiratory andenteric diseases in pigs and poultry is an anti-infective treatmentfor respiratory and enteric diseases in animals. Over the past year,the company achieved 4% revenue growth, surpassing marketexpectations. Hallas highlighted strong growth in Latin America andSouth and Southeast Asia, driven by increasing demand for high-qualitywhite meat.
Looking ahead, Eco Animal Health plans to diversifyinto preventative disease solutions, such as vaccines and monoclonalantibodies, targeting the US market by the end of next year. Hallasalso addressed misconceptions, emphasising that the company'sgrowth is not solely reliant on the Chinese market and that a balancedapproach of prevention and treatment is essential forsuccess.
Contact Details
Proactive UKLtd
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.